PAVM on Nasdaq
PAVmed Inc.
In its 2026 annual report the company says: “PAVmed is a diversified commercial-stage life sciences company operating in the medical device, diagnostics, and digital health sectors. It operates through multiple independently financed subsidiaries under a shared services model.”5 It is headquartered in New York, United States.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with VIVOS INC, Fractyl (United States) or Profusa, Inc., or pick any stock.
- TickerPAVM on Nasdaq2
- IndustrySurgical & Medical Instruments & Apparatus2
- HeadquartersNew York, United States2
- Incorporated inDE3
- Business address360 Madison Avenue, 25Th Floor, New York, Ny 100173
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI549300V1JXXVXU7P80072
- StatusActive2
- LEI statusIssued and current2
- Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 55592102
See how the biggest companies compare on our leaderboards
PAVmed is a diversified commercial-stage life sciences company operating in the medical device, diagnostics, and digital health sectors. It operates through multiple independently financed subsidiaries under a shared services model. The Company’s strategy is to advance and commercialize innovative healthcare technologies through its subsidiaries while maintaining flexibility to structure financing at either the PAVmed level or within its subsidiaries.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue4¢$218.0K
- Research and development88¢$4.5M
- Profit8¢$401.0K
Out of $71.0K in revenue.6
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $71.0K | $3.0M |
| Cost of revenue | $218.0K | $4.8M |
| Sales and marketing | $917.0K | $11.6M |
| General and administrative | $16.2M | $24.5M |
| Amortization of acquired intangible assets | $0 | $559.0K |
| Research and development | $4.5M | $5.9M |
| Total operating expenses | $21.9M | $47.5M |
| Operating loss | -$21.8M | -$44.5M |
| Interest income | $29.0K | $254.0K |
| Interest expense | -$21.0K | -$45.0K |
| Gain on deconsolidation of subsidiary | $0 | $72.3M |
| Change in fair value - equity method investment | $8.5M | $532.0K |
| Change in fair value - Senior Secured Convertible Notes | -$3.3M | $462.0K |
| Debt extinguishments loss - Senior Secured Convertible Notes | -$58.0K | -$2.5M |
| Debt modification expense | $0 | -$2.0M |
| Management fee income | $13.8M | $3.9M |
| Grant income | $416.0K | $109.0K |
| Other income (expense), net | $19.3M | $72.9M |
| Income (loss) before provision for income tax | -$2.5M | $28.4M |
| Provision for income taxes | $0 | $0 |
| Net income (loss) before noncontrolling interests | -$2.5M | $28.4M |
| Net loss attributable to the noncontrolling interests | $2.9M | $11.4M |
| Net income (loss) attributable to PAVmed Inc. | $401.0K | $39.8M |
| Net income (loss) attributable to PAVmed Inc. common stockholders | -$3.8M | $32.0M |
| Net income (loss) per share attributable to PAVmed Inc. common stockholders basic (in dollars per share) | -$5.63 | $99.15 |
| Net income (loss) per share attributable to PAVmed Inc. common stockholders diluted (in dollars per share) | -$5.63 | $14.90 |
| Weighted average common shares outstanding, basic (in shares) | 670.5K shares | 322.4K shares |
| Weighted average common shares outstanding, diluted (in shares) | 670.5K shares | 2.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2025-10-31 | 2024-12-31 | 2023-12-31 | 2023-03-31 |
|---|---|---|---|---|---|
| Cash | $1.5M | $1.2M | |||
| Accounts receivable | $15.0K | $18.0K | |||
| Prepaid expenses, deposits, and other current assets | $1.0M | $961.0K | |||
| Total current assets | $2.6M | $2.2M | |||
| Fixed assets, net | $77.0K | $151.0K | |||
| Operating lease right-of-use assets | $2.0M | $2.5M | |||
| Equity method investment - at fair value | $34.1M | $25.6M | |||
| Other assets | $56.0K | $208.0K | |||
| Total assets | $38.8M | $30.7M | |||
| Accounts payable | $678.0K | $657.0K | |||
| Accrued expenses and other current liabilities | $2.5M | $5.2M | |||
| Operating lease liabilities, current portion | $573.0K | $513.0K | |||
| Senior Secured Convertible Notes - at fair value | $11.1M | $29.1M | |||
| Total current liabilities | $14.8M | $35.4M | |||
| Operating lease liabilities, less current portion | $1.7M | $2.2M | |||
| Total liabilities | $16.5M | $37.7M | |||
| Common stock, $0.001 par value. Authorized, 25,000,000 shares (Note 15); 927,934 and 373,300 shares outstanding as of December 31, 2025 and December 31, 2024, respectively | $1.0K | $1.0K | |||
| Additional paid-in capital | $268.0M | $249.2M | |||
| Accumulated deficit | -$258.7M | -$255.0M | |||
| Total PAVmed Inc. Stockholders Equity (Deficit) | $34.0M | -$2.5M | |||
| Noncontrolling interests | -$11.7M | -$4.5M | |||
| Total Stockholders Equity (Deficit) | $22.3M | -$7.0M | -$24.0M | ||
| Total liabilities and stockholders equity | $38.8M | $30.7M | |||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |||
| Preferred stock, shares authorized (in shares) | 20.0M shares | 20.0M shares | |||
| Common stock, par or stated value (in dollars per share) | $0.00 | $0.00 | |||
| Common stock, shares authorized (in shares) | 25.0M shares | 25.0M shares | 25.0M shares | 250.0M shares | |
| Common stock, shares outstanding (in shares) | 927.9K shares | 373.3K shares | |||
| Common stock, shares issued (in shares) | 927.9K shares | 373.3K shares |
| Period ending | 2025-12-31 | 2025-10-31 | 2024-12-31 | 2023-12-31 | 2023-03-31 |
|---|---|---|---|---|---|
| Cash | $1.5M | $1.2M | |||
| Accounts receivable | $15.0K | $18.0K | |||
| Prepaid expenses, deposits, and other current assets | $1.0M | $961.0K | |||
| Total current assets | $2.6M | $2.2M | |||
| Fixed assets, net | $77.0K | $151.0K | |||
| Operating lease right-of-use assets | $2.0M | $2.5M | |||
| Equity method investment - at fair value | $34.1M | $25.6M | |||
| Other assets | $56.0K | $208.0K | |||
| Total assets | $38.8M | $30.7M | |||
| Accounts payable | $678.0K | $657.0K | |||
| Accrued expenses and other current liabilities | $2.5M | $5.2M | |||
| Operating lease liabilities, current portion | $573.0K | $513.0K | |||
| Senior Secured Convertible Notes - at fair value | $11.1M | $29.1M | |||
| Total current liabilities | $14.8M | $35.4M | |||
| Operating lease liabilities, less current portion | $1.7M | $2.2M | |||
| Total liabilities | $16.5M | $37.7M | |||
| Common stock, $0.001 par value. Authorized, 25,000,000 shares (Note 15); 927,934 and 373,300 shares outstanding as of December 31, 2025 and December 31, 2024, respectively | $1.0K | $1.0K | |||
| Additional paid-in capital | $268.0M | $249.2M | |||
| Accumulated deficit | -$258.7M | -$255.0M | |||
| Total PAVmed Inc. Stockholders Equity (Deficit) | $34.0M | -$2.5M | |||
| Noncontrolling interests | -$11.7M | -$4.5M | |||
| Total Stockholders Equity (Deficit) | $22.3M | -$7.0M | -$24.0M | ||
| Total liabilities and stockholders equity | $38.8M | $30.7M | |||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |||
| Preferred stock, shares authorized (in shares) | 20.0M shares | 20.0M shares | |||
| Common stock, par or stated value (in dollars per share) | $0.00 | $0.00 | |||
| Common stock, shares authorized (in shares) | 25.0M shares | 25.0M shares | 25.0M shares | 250.0M shares | |
| Common stock, shares outstanding (in shares) | 927.9K shares | 373.3K shares | |||
| Common stock, shares issued (in shares) | 927.9K shares | 373.3K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) - before noncontrolling interest (NCI) | -$2.5M | $28.4M |
| Depreciation and amortization expense | $105.0K | $1.2M |
| Stock-based compensation | $1.7M | $6.4M |
| Gain on deconsolidation of subsidiary | $0 | -$72.3M |
| Change in fair value - equity method investment | -$8.5M | -$532.0K |
| Issuance of stock for services | $505.0K | $598.0K |
| Change in fair value - Senior Secured Convertible Notes | $3.3M | -$462.0K |
| Debt extinguishment loss - Senior Secured Convertible Note | $58.0K | $2.5M |
| Non-cash lease expense | -$16.0K | $8.0K |
| Accounts receivable | $3.0K | $43.0K |
| Prepaid expenses, deposits and current and other assets | $109.0K | $832.0K |
| Accounts payable | $24.0K | -$59.0K |
| Accrued expenses and other current liabilities | -$38.0K | -$304.0K |
| Net cash flows used in operating activities | -$5.2M | -$33.6M |
| Purchase of equipment | -$31.0K | -$55.0K |
| Decrease in cash due to deconsolidation of subsidiary | $0 | -$16.5M |
| Net cash flows provided by (used in) investing activities | -$31.0K | -$16.2M |
| Payment financing costs debt exchange | -$109.0K | $0 |
| Payment Senior Secured Convertible Note acceleration floor payments | $0 | -$531.0K |
| Proceeds issue common stock Employee Stock Purchase Plan | $0 | $62.0K |
| Net cash flows provided by financing activities | $5.6M | $31.3M |
| Net increase (decrease) in cash | $353.0K | -$18.5M |
No quarter-by-quarter statement was filed.
Corporate structure
PAVmed Inc. sits at the top of its group. 10 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of PAVmed Inc.
- David S. Nagelberg Filed SCHEDULE 13G/A on PAVmed Inc., latest Aug 13, 2026 (2 filings since Apr 8, 2026)
- Two Seas Capital LP Filed SCHEDULE 13G on PAVmed Inc., latest May 15, 2026
- FIRST MANHATTAN CO. LLC. Filed SCHEDULE 13G on PAVmed Inc., latest May 14, 2026 (3 filings since Nov 14, 2024)
- Ayrton Capital LLC Filed SCHEDULE 13G/A on PAVmed Inc., latest May 11, 2026 (3 filings since Feb 14, 2024)
- Tasso Partners, LLC Filed SCHEDULE 13G/A on PAVmed Inc., latest Apr 14, 2026 (3 filings since Feb 28, 2025)
- Scopia Holdings LLC Filed SCHEDULE 13G on PAVmed Inc., latest Apr 13, 2026
- Lishan Aklog Filed SCHEDULE 13D on PAVmed Inc., latest Apr 9, 2026
- Scott Dols V. Filed SCHEDULE 13G on PAVmed Inc., latest Apr 8, 2026
- Craig Kallman Filed SCHEDULE 13G on PAVmed Inc., latest Apr 3, 2026
- Sargent Investment Group, LLC Filed SCHEDULE 13G on PAVmed Inc., latest Aug 14, 2025
- Anthony Michael Dubreville Filed SC 13G on PAVmed Inc., latest Sep 23, 2024
- BlackRock Filed SC 13G on PAVmed Inc., latest Jul 8, 2022 (2 filings since Feb 4, 2022)
- PAVmed Inc. New York, New York, United States
- Lucid Diagnostics Inc. Stake · New York, New York
- CapNostics LLC (84-4876240) Subsidiary · North Carolina, United States
- Lucid Diagnostics Inc. (82-5488042) Subsidiary · Delaware, United States
- LucidDx Labs Inc. (87-41661458) Subsidiary · Delaware, United States
- Oncodisc Inc (82-4885133) Subsidiary · Delaware, United States
- PAVmed Subsidiary Corp Inc. (81-1637646) Subsidiary · Delaware, United States
- PAVmedX Corp (99-3191604) Subsidiary · Delaware, United States
- PortIO Corp (99-3046573) Subsidiary · Delaware, United States
- Veris Health Inc. (87-0983820) Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.
What it owns
What PAVmed Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $1.4M6 Dec 31, 2025 | $1.4M6 Dec 31, 2024 | +2.2% |
| Accumulated depreciation | $1.4M6 Dec 31, 2025 | $1.3M6 Dec 31, 2024 | +8.4% |
| Property and equipment, net | $77.0K6 Dec 31, 2025 | $151.0K6 Dec 31, 2024 | −49.0% |
| Operating-lease assets (leased space) | $2.0M6 Dec 31, 2025 | $2.5M6 Dec 31, 2024 | −19.9% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $1.5M6 Dec 31, 2025 | $1.2M6 Dec 31, 2024 | +29.8% |
| Stakes in other companies (equity method) | $34.1M6 Dec 31, 2025 | $25.6M6 Dec 31, 2024 | +33.1% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Finite-lived intangibles, gross | $70.0K9 Dec 31, 2024 | $5.4M9 Dec 31, 2023 | −98.7% |
| Accumulated amortization | $70.0K9 Dec 31, 2024 | $4.0M9 Dec 31, 2023 | −98.2% |
Properties, in its own words
Our corporate offices are located at 360 Madison Avenue, 25th Floor, New York, NY 10017. The lease for this space is for seven years and eight months, starting on February 1, 2023, and may not be terminated prior to expiration of its stated term, except in limited circumstances due to misconduct by our landlord. The Company or its subsidiaries also have entered into leases for a research and development facility in Massachusetts with 7,375 square feet, which has a remaining term expiring April 30, 2027 and an office space in Pennsylvania with 4,300 square feet, which has a remaining term expiring October 31, 2027. At this time, we consider our facility space to be commensurate with our current operations. Notwithstanding, we may obtain additional space in the future, as warranted by our business operations.
Item 2 of the 10-K filed Mar 27, 2026.5
Leadership
Who has led PAVmed Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
President
Chief financial officer
Chief operating officer
- Chief executive officerLishan Aklog Jan 29, 2016 to now16
- ChairLishan Aklog May 2, 2016 to now17
- PresidentDennis M. McGrath May 28, 2019 to now18
- Chief financial officerDennis M. McGrath Mar 21, 2017 to now19
- Chief financial officerRichard F. Fitzgerald Jan 29, 2016 to Jun 3, 201620
- Chief operating officerShaun O'Neil Feb 24, 2022 to now21
Board members and other officers (15)
- Chief Medical OfficerVictoria Tou-Ho Lee Apr 13, 2026 to now22
- Chief Medical OfficerBrian J. Deguzman Jan 29, 2016 to Feb 23, 202223
- Vice chairMichael J. Glennon Jan 29, 2016 to Apr 5, 202124
- Board memberSundeep Agrawal Sep 20, 2024 to now25
- Board memberJoan B. Harvey Feb 18, 2022 to Feb 23, 202426
- Board memberTimothy E. Baxter Mar 1, 2022 to now27
- Board memberDebra White May 3, 2021 to now28
- Board memberDavid S. Battleman Aug 11, 2017 to Apr 5, 202129
- Board memberDavid Weild Iv. Jan 29, 2016 to Apr 5, 202130
- Board memberIra Scott Greenspan Jan 29, 2016 to Feb 14, 201831
- Board memberJames L. Cox Jan 29, 2016 to Feb 23, 202432
- Board memberJoshua R. Lamstein Jan 29, 2016 to Dec 26, 201733
- Board memberLishan Aklog Jan 29, 2016 to Jan 29, 201616
- Board memberMichael J. Glennon Jan 29, 2016 to now24
- General counselMichael Adam Gordon Jun 8, 2022 to now34
Named in SEC Form D filings
People the company listed in its private-offering notices.
- DirectorRonald M. Sparks named Feb 7, 2025 to Feb 17, 202635
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- CapNostics LLC (84-4876240) North Carolina4
- Lucid Diagnostics Inc. (82-5488042) Delaware4
- LucidDx Labs Inc. (87-41661458) Delaware4
- Oncodisc Inc (82-4885133) Delaware4
- PAVmed Subsidiary Corp Inc. (81-1637646) Delaware4
- PAVmedX Corp (99-3191604) Delaware4
- PortIO Corp (99-3046573) Delaware4
- Veris Health Inc. (87-0983820) Delaware4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- PAXmed Inc.Nov 19, 2014 to Mar 26, 20153
Timeline
- Sep 10, 20268-K Entered a material agreement36
- Aug 14, 20268-K Results of operations; Regulation FD disclosure37
- Jun 24, 20268-K Executive or director change; Shareholder vote38
- May 15, 20268-K Results of operations; Regulation FD disclosure39
- Mar 30, 20268-K Results of operations; Regulation FD disclosure40
- Mar 27, 20268-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote41
- Feb 4, 20268-K Entered a material agreement; Ended a material agreement; New debt or obligation42
- Jan 23, 20268-K Other events43
- Dec 30, 20258-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure44
- Dec 5, 20258-K Shareholder vote45
- Nov 13, 20258-K Results of operations; Regulation FD disclosure46
- Sep 11, 20258-K Other events47
- Jan 29, 2016New chief executive Lishan Aklog becomes CEO16
- Jun 26, 2014Founded PAVmed Inc. is founded2
Calendar
Coming up
- Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($8.71) a share, on Nov 13, 2025.48
When it reported results
- Aug 14, 2026Reported quarterly or annual results37
- May 15, 2026Reported quarterly or annual results39
- Mar 30, 2026Reported quarterly or annual results40
- Nov 13, 2025Reported quarterly or annual results46
- Aug 14, 2025Reported quarterly or annual results49
- May 15, 2025Reported quarterly or annual results50
- Mar 25, 2025Reported quarterly or annual results51
- Nov 14, 2024Reported quarterly or annual results52
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
250 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 78 major events, 58 insider forms, 21 large holders, 2 private raises, 71 other. The latest 20:
- Sep 10, 20268-K EDGAR
- Sep 10, 2026424B5 EDGAR
- Aug 14, 20268-K EDGAR
- Aug 13, 202610-Q EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Jul 30, 2026S-8 EDGAR
- Jun 24, 20268-K EDGAR
- May 15, 20268-K EDGAR
- May 15, 2026SCHEDULE 13G EDGAR
- May 14, 202610-Q EDGAR
- May 14, 2026SCHEDULE 13G EDGAR
- May 11, 2026SCHEDULE 13G/A EDGAR
- Apr 30, 2026DEFA14A EDGAR
- Apr 30, 2026ARS EDGAR
- Apr 30, 2026DEF 14A EDGAR
- Apr 29, 2026EFFECT EDGAR
- Apr 29, 2026424B3 EDGAR
- Apr 27, 2026CORRESP EDGAR
- Apr 24, 2026UPLOAD EDGAR
- Apr 21, 2026S-3 EDGAR
The 250 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 7, 2022 | Glennon Michael JDirector | Buy | 100,000 | $0.62 | $62.0K | Form 4 |
| Dec 6, 2022 | Glennon Michael JDirector | Buy | 88,000 | $0.64 | $56.3K | Form 4 |
| Dec 5, 2022 | Glennon Michael JDirector | Buy | 62,000 | $0.69 | $42.8K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- David S. NagelbergSCHEDULE 13G/A, 2 filings Apr 8, 2026 to Aug 13, 202653
- Two Seas Capital LPSCHEDULE 13G, 1 filing May 15, 202654
- FIRST MANHATTAN CO. LLC.SCHEDULE 13G, 3 filings Nov 14, 2024 to May 14, 202655
- Ayrton Capital LLCSCHEDULE 13G/A, 3 filings Feb 14, 2024 to May 11, 202656
- Tasso Partners, LLCSCHEDULE 13G/A, 3 filings Feb 28, 2025 to Apr 14, 202657
- Scopia Holdings LLCSCHEDULE 13G, 1 filing Apr 13, 202658
- Lishan AklogSCHEDULE 13D, 1 filing Apr 9, 202659
- Scott Dols V.SCHEDULE 13G, 1 filing Apr 8, 202660
- Craig KallmanSCHEDULE 13G, 1 filing Apr 3, 202661
- Sargent Investment Group, LLCSCHEDULE 13G, 1 filing Aug 14, 202562
- Anthony Michael DubrevilleSC 13G, 1 filing Sep 23, 202463
- BlackRockSC 13G, 2 filings Feb 4, 2022 to Jul 8, 202264
- Matthew SirovichSC 13G/A, 1 filing Oct 6, 202165
Stakes it holds
PAVmed Inc. has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).
- Lucid Diagnostics Inc.SCHEDULE 13D/A Oct 27, 2021 to Feb 9, 202666
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Lishan AklogM.D. | 60 | $613.0K | $1.0M67 |
| 2025 | Dennis M. McGrath | 69 | $438.0K | $667.0K67 |
| 2025 | Michael A. Gordon | 52 | $450.0K | $638.2K67 |
| 2025 | Shaun M. O’Neil | 44 | $325.0K | $482.0K67 |
| 2024 | Chairman of the Board and Chief Executive Officer | $613.0K | $663.5K67 | |
| 2024 | General Counsel and Secretary | $450.0K | $460.9K67 | |
| 2024 | President and Chief Financial Officer | $438.0K | $448.9K67 | |
| 2024 | Chief Operating Officer | $325.0K | $335.9K67 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $32.7M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2026 | $30.0M | $30.0M |
| 2025 | $2.7M | $2.7M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Two Seas Capital LP | 461,539 | $2.7M | 0.1% | No change |
| First Manhattan Co. Llc. | 332,911 | $2.0M | 0.0% | +309,106 |
| Vanguard Capital Management LLC | 61,604 | $365.9K | 0.0% | +55,687 |
| Geode Capital Management, LLC | 36,678 | $217.9K | 0.0% | +24,901 |
| Vanguard Fiduciary Trust Co | 25,605 | $152.1K | 0.0% | +20,176 |
| BlackRock, Inc. | 17,092 | $101.5K | 0.0% | +14,676 |
| Morgan Stanley | 163 | $968 | 0.0% | −2 |
| Barclays PLC | 75 | $446 | 0.0% | New |
| SBI Securities Co., Ltd. | 67 | $398 | 0.0% | No change |
| UBS Group AG | 57 | $339 | 0.0% | −18 |
| Wells Fargo & Company/mn | 45 | $267 | 0.0% | No change |
| Integrated Wealth Concepts LLC | 13 | $78 | 0.0% | New |
| Allworth Financial LP | 5 | $30 | 0.0% | −1 |
| Federation des caisses Desjardins du Quebec | 4 | $23 | 0.0% | New |
| Osaic Holdings, Inc. | 4 | $21 | 0.0% | No change |
| Steward Partners Investment Advisory, LLC | 2 | $12 | 0.0% | +1 |
| Bnp Paribas Financial Markets | 1 | $6 | 0.0% | No change |
| Caitong International Asset Management Co., Ltd | 1 | $6 | 0.0% | New |
| Jones Financial Companies Lllp | 1 | $5 | 0.0% | No change |
| Royal Bank Of Canada | 1 | $0 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How PAVmed Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARPAVmed Inc.1
- CIK0001624326
- Employer ID (EIN)47-12141775
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address360 Madison Avenue, 25Th Floor, New York, NY 100171
- Phone(212) 949-43191
- Shares outstanding7,995,918 as of Aug 13, 202614
- Public float$11.8M as of Jun 30, 20245
- AuditorMarcum LLP, New York, NY PCAOB ID 199; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceNov 19, 20141
- Filings688 in all: 8-K (185), 4 (148), 10-Q (32), 3 (22), CORRESP (21), UPLOAD (20), S-1/A (17), S-8 (17)1
All 56 form types
424B3 (15), 424B5 (15), DEF 14A (15), EFFECT (14), 10-K (11), PRE 14A (11), S-3 (10), SC 13D/A (10), D (9), DEFA14A (8), SCHEDULE 13G (8), SC 13G (7), SC TO-I/A (7), FWP (6), S-3/A (6), SCHEDULE 13G/A (6), S-1 (5), SC 13G/A (5), 10-K/A (4), 144 (4), 5 (4), NT 10-Q (4), SC TO-C (4), 10-Q/A (3), 25-NSE (3), ARS (3), NT 10-K (3), 4/A (2), 8-A12B (2), SC 13D (2), SC TO-I (2), SCHEDULE 13D/A (2), 3/A (1), 424B4 (1), 8-K/A (1), CERT (1), CERTNAS (1), D/A (1), DEF 14C (1), DEL AM (1), DRS (1), DRS/A (1), DRSLTR (1), PRE 14C (1), RW (1), S-3MEF (1), S-4 (1), SCHEDULE 13D (1)
- Latest filingsAnnual report (10-K) Mar 27, 2026
Quarterly report (10-Q) Aug 13, 2026
Proxy statement (DEF 14A) Apr 30, 2026
Latest 8-K (8-K) Sep 10, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 par value per share | PAVM | The NASDAQ Stock Market LLC |
From the cover page of the 10-K filed Mar 27, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks PAVmed Inc. names in Item 1A of its 10-K filed Mar 27, 2026: 49 risks under these headings, as written.5
- Risks Related to Financial Position and Capital Resources
- Risks Associated with Our Business
- Risks Associated with Healthcare Regulation, Billing and Reimbursement, and Product Safety and Effectiveness
- Risks Associated with Ownership of Our Common Stock
- We have incurred operating losses since our inception and may not be able to achieve profitability.
- We have concluded there is substantial doubt of our ability to continue as a going concern and our independent registered public accounting firm’s report on our financial statements contains an explanatory paragraph describing our ability to continue as a going concern.
- We and our subsidiaries have faced significant challenges raising capital under the current market conditions.
- There can be no assurance that our common stock will continue to trade on the Nasdaq Capital Market or another national securities exchange.
- Our subsidiary Lucid may issue shares of its common and/or preferred stock in the future. These events could reduce the percentage equity interest of PAVmed in Lucid, and thereby reduce its influence over matters subject to a shareholder vote and otherwise adversely affect your investment in PAVmed.
- Servicing our indebtedness may require a significant amount of cash, and the restrictive covenants contained in the documents that govern our indebtedness and preferred stock could adversely affect our business plan, liquidity, financial condition, and results of operations.
- We will need substantial additional funding and may be unable to raise capital when needed, which could force us to delay, reduce, eliminate or abandon growth initiatives or product development programs.
- The markets in which we operate are highly competitive, and we may not be able to effectively compete against other providers of medical devices, particularly those with greater resources.
The other 40 risks
- We have finite resources, which may restrict our success in commercializing our current products and other products we may develop, and we may be unsuccessful in entering into or maintaining third-party arrangements to support our internal efforts.
- If we are unable to deploy and maintain effective sales, marketing and medical affairs capabilities, we will have difficulty achieving market awareness and selling our tests and other products.
- Our products may never achieve market acceptance.
- Recommendations, guidelines and quality metrics issued by various organizations may significantly affect payors’ willingness to cover, and healthcare providers’ willingness to prescribe, our products.
- We or our third-party manufacturers may not have the manufacturing and processing capacity to meet the production requirements of clinical testing or consumer demand in a timely manner.
- If demand for our EsoGuard test grows, we may lack adequate facility space and capabilities to meet increased processing requirements. Moreover, if these or any future facilities or our equipment were damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business could be materially harmed.
- We may make investments in products we have not yet developed, and those investments may not be realized.
- Our products and services may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business.
- Our products and services may cause serious adverse side effects or even death or have other properties that could delay or prevent their regulatory approval, limit the commercial desirability of an approved label or result in significant negative consequences following any marketing approval.
- Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
- We may not be able to protect or enforce our intellectual property rights, which could impair our competitive position.
- We may be subject to intellectual property infringement claims by third parties which could be costly to defend, divert management’s attention and resources, and may result in liability.
- Competitors may violate our intellectual property rights, and we may bring litigation to protect and enforce our intellectual property rights, which may result in substantial expense and may divert our attention from implementing our business strategy.
- Our business may suffer if we are unable to manage our growth.
- Our ability to be successful will be totally dependent upon the efforts of our key personnel.
- Our officers and directors have fiduciary obligations to other companies and, accordingly, may have conflicts of interest in determining to which entity a particular business opportunity should be presented.
- Our business, financial condition and results of operations could be adversely affected by the political and economic conditions of the countries in which we conduct business.
- Failure in our information technology or storage systems could significantly disrupt our operations and our research and development efforts, which could adversely impact our revenues, as well as our research, development and commercialization efforts.
- We may become the subject of various claims, threats of litigation, litigation or investigations which could have a material adverse effect on our business, financial condition, results of operations or price of our common stock.
- If private or governmental third-party payors do not maintain reimbursement for our products at adequate reimbursement rates, we may be unable to successfully commercialize our products which would limit or slow our revenue generation and likely have a material adverse effect on our business.
- Any future products or services we may develop may not be approved for sale in the U.S. or in any other country. In order to obtain approval, we may need to conduct clinical trials necessary to support a FDA 510(k) notice or PMA application will be expensive and will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.
- The results of the Company’s clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.
- Even if we receive regulatory approval for any product we may develop, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements.
- Healthcare reform measures, including those targeting Medicare or Medicaid, could hinder or prevent our products’ commercial success.
- If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
- The Company’s medical products may in the future be subject to product recalls that could harm its reputation, business and financial results.
- If the Company’s medical products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.
- If the Company is found to be promoting the use of its devices for unapproved or “off-label” uses or engaging in other noncompliant activities, the Company may be subject to recalls, seizures, fines, penalties, injunctions, adverse publicity, prosecution, or other adverse actions, resulting in damage to its reputation and business.
- We may issue shares of our common and/or preferred stock in the future (including shares of our common stock upon exercise of the outstanding Series D warrants) which could reduce the equity interest of our stockholders and might cause a change in control of our ownership.
- The holder of our debt has certain rights with respect to the shares in Lucid Diagnostics that we own, which may have a material impact on the return on any investment in shares of our common stock.
- A robust public market for our common stock may not be sustained, which could affect your ability to sell our common stock or depress the market price of our common stock.
- Our stock price may be volatile, and purchasers of our securities could incur substantial losses.
- Our outstanding warrants and other convertible securities may have an adverse effect on the market price of our common stock and the value of your investment in us.
- We do not intend to pay any cash dividends on our common stock at this time.
- We have made distributions of shares of Lucid common stock to our shareholders in the past, but there is no assurance we will do so in the future.
- We are subject to evolving corporate governance and public disclosure expectations and regulations that impact compliance costs and risks of noncompliance.
- We incur significant costs as a result of our and Lucid Diagnostics operating as a public company, and our management will be required to devote substantial time to compliance initiatives.
- If we experience material weaknesses in our internal control over financial reporting in the future, our business may be harmed.
- If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.
- Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.
Legal proceedings
In the ordinary course of the Company’s business, particularly as it begins commercialization of its products, the Company may be subject to legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company is not aware of any such pending legal or other proceedings that are reasonably likely to have a material impact on the Company. Notwithstanding, legal proceedings are subject to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARPAVmed Inc. filings on SEC EDGAR
- 2
- 3SEC EDGARPAVmed Inc. filings on SEC EDGAR
- 4
- 5
- 6SEC EDGARPAVmed Inc. 10-K for fiscal 2025
- 7SEC EDGARPAVmed Inc. 10-K for fiscal 2021
- 8SEC EDGARPAVmed Inc. 10-K for fiscal 2022
- 9SEC EDGARPAVmed Inc. 10-K for fiscal 2023
- 10SEC EDGARPAVmed Inc. 10-K for fiscal 2021
- 11SEC EDGARPAVmed Inc. 10-K for fiscal 2019
- 12SEC EDGARPAVmed Inc. 10-Q for fiscal 2025
- 13SEC EDGARPAVmed Inc. 10-Q for fiscal 2026
- 14SEC EDGARPAVmed Inc. 10-Q for fiscal 2026
- 15SEC EDGARPAVmed Inc. 10-K for fiscal 2019
- 16
- 17SEC EDGARLishan Aklog, Chair
- 18SEC EDGARDennis M. McGrath, President
- 19
- 20
- 21
- 22
- 23
- 24SEC EDGARMichael J. Glennon, Vice chair
- 25SEC EDGARSundeep Agrawal, Board member
- 26SEC EDGARJoan B. Harvey, Board member
- 27SEC EDGARTimothy E. Baxter, Board member
- 28SEC EDGARDebra White, Board member
- 29SEC EDGARDavid S. Battleman, Board member
- 30SEC EDGARDavid Weild Iv., Board member
- 31SEC EDGARIra Scott Greenspan, Board member
- 32SEC EDGARJames L. Cox, Board member
- 33SEC EDGARJoshua R. Lamstein, Board member
- 34SEC EDGARMichael Adam Gordon, General counsel
- 35
- 36SEC EDGAREntered a material agreement
- 37
- 38
- 39
- 40
- 41
- 42
- 43SEC EDGAROther events
- 44
- 45SEC EDGARShareholder vote
- 46
- 47SEC EDGAROther events
- 48NasdaqNasdaq calendar
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64SEC EDGARBlackRock SC 13G on PAVmed Inc.
- 65
- 66
- 67
- 68